Bausch+Lomb ($BLCO), a contact lens supplier, is exploring a sale to address concerns raised by its lenders like Apollo ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

The stock of eyecare company Bausch + Lomb Corp. was up 18% early Monday, after the Financial Times reported that the company ...

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned ...

Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Bausch + Lomb is projected to generate nearly $860mn in adjusted earnings before interest, taxation, depreciation and ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Bausch + Lomb is working with advisers from Goldman Sachs to test interest from possible buyers, the Financial Times reported ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...